PIQ has always been a long term play - Fundamentals have only improved, analytics division showing strong sales revenue and new partnership with CPR will provide more industry exposure to PIQ.
Revenue at around $1.5M with market cap of $15M gives us a revenue to market cap multiplier of x10 which is very cheap in my opinion. Adding over $3M in Cash and looking at the long term market trend towards Biosimilars and Biologics, I think PIQ is significantly undervalued.
PIQ has always been a long term play - Fundamentals have only...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $187.1K | 634.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 81754 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 15.57pm 27/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |